These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 25938550)

  • 1. Setting up a Nuchal Translucency Clinic: What Radiologists Need to Know.
    Onyeacholem I; Kleiner B; Hull AD; Chibuk J; Romine L; Anton T; Pretorius DH
    Ultrasound Q; 2016 Mar; 32(1):3-14. PubMed ID: 25938550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening for structural fetal anomalies during the nuchal translucency ultrasound examination.
    Weiner Z; Goldstein I; Bombard A; Applewhite L; Itzkovits-Eldor J
    Am J Obstet Gynecol; 2007 Aug; 197(2):181.e1-5. PubMed ID: 17689643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks.
    Falcon O; Auer M; Gerovassili A; Spencer K; Nicolaides KH
    Ultrasound Obstet Gynecol; 2006 Feb; 27(2):151-5. PubMed ID: 16388509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective validation of first-trimester combined screening for trisomy 21.
    Kagan KO; Etchegaray A; Zhou Y; Wright D; Nicolaides KH
    Ultrasound Obstet Gynecol; 2009 Jul; 34(1):14-8. PubMed ID: 19526452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maternal serum biochemistry at 11-13(+6) weeks in relation to the presence or absence of the fetal nasal bone on ultrasonography in chromosomally abnormal fetuses: an updated analysis of integrated ultrasound and biochemical screening.
    Cicero S; Spencer K; Avgidou K; Faiola S; Nicolaides KH
    Prenat Diagn; 2005 Nov; 25(11):977-83. PubMed ID: 16245371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Study on several ultrasound markers combined maternal serum biochemical markers to screen fetal chromosomal aneuploidy at 11 to 13(+)6 weeks of gestation].
    Chen X; Chang Y; Cui HY; Ren CC; Yu BY
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):815-8. PubMed ID: 24444556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening for trisomy 21 with maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-14 weeks: a regional experience from Germany.
    Soergel P; Pruggmayer M; Schwerdtfeger R; Muhlhaus K; Scharf A
    Fetal Diagn Ther; 2006; 21(3):264-8. PubMed ID: 16601335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of deviation of nuchal translucency measurements on the performance of screening for trisomy 21.
    Kagan KO; Wright D; Etchegaray A; Zhou Y; Nicolaides KH
    Ultrasound Obstet Gynecol; 2009 Jun; 33(6):657-64. PubMed ID: 19408250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fetal echocardiography at the time of the nuchal translucency scan.
    Lombardi CM; Bellotti M; Fesslova V; Cappellini A
    Ultrasound Obstet Gynecol; 2007 Mar; 29(3):249-57. PubMed ID: 17318942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Ultrasound screening for Down syndrome and other chromosomal abnormalities by fetal nuchal translucency measurement between 11-14 weeks of gestation].
    Dimitrova V; Markov D; Chernev T; Karag'ozova Zh; Mazneĭkova V; Andonova S; Vŭzharova R
    Akush Ginekol (Sofiia); 2005; 44(1):32-7. PubMed ID: 15853009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrated ultrasound and biochemical screening for trisomy 21 using fetal nuchal translucency, absent fetal nasal bone, free beta-hCG and PAPP-A at 11 to 14 weeks.
    Cicero S; Bindra R; Rembouskos G; Spencer K; Nicolaides KH
    Prenat Diagn; 2003 Apr; 23(4):306-10. PubMed ID: 12673635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening for trisomy 21 by maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-14 weeks: a German multicenter study.
    von Kaisenberg CS; Gasiorek-Wiens A; Bielicki M; Bahlmann F; Meyberg H; Kossakiewicz A; Pruggmayer M; Kamin G; Fritzer E; Harris C; Arnold N;
    J Matern Fetal Neonatal Med; 2002 Aug; 12(2):89-94. PubMed ID: 12420837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-trimester Down syndrome screening: component analytes and timing for optimal performance.
    Wenstrom KD
    Semin Perinatol; 2005 Aug; 29(4):195-202. PubMed ID: 16104668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The nuchal translucency examination leading to early diagnosis of structural fetal anomalies.
    Goldstein I; Weizman B; Nizar K; Weiner Z
    Early Hum Dev; 2014 Feb; 90(2):87-91. PubMed ID: 24411497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive value of increased nuchal translucency as a screening test for the detection of fetal chromosomal abnormalities.
    Alexioy E; Alexioy E; Trakakis E; Kassanos D; Farmakidis G; Kondylios A; Laggas D; Salamalekis E; Florentin L; Kanavakis E; Basios G; Trompoukis P; Georgiadoy L; Panagiotopoulos T
    J Matern Fetal Neonatal Med; 2009 Oct; 22(10):857-62. PubMed ID: 19521928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of maternal insulin-dependent diabetes on fetal nuchal translucency thickness and first-trimester maternal serum biochemical markers of aneuploidy.
    Spencer K; Cicero S; Atzei A; Otigbah C; Nicolaides KH
    Prenat Diagn; 2005 Oct; 25(10):927-9. PubMed ID: 16088864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased nuchal translucency thickness and normal karyotype: time for parental reassurance.
    Bilardo CM; Müller MA; Pajkrt E; Clur SA; van Zalen MM; Bijlsma EK
    Ultrasound Obstet Gynecol; 2007 Jul; 30(1):11-8. PubMed ID: 17559183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SURUSS in perspective.
    Wald NJ; Rodeck C; Hackshaw AK; Rudnicka A
    Semin Perinatol; 2005 Aug; 29(4):225-35. PubMed ID: 16104673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reference centile chart for fetal nuchal translucency, maternal serum PAPP-A and free beta hCG.
    Chawanpaiboon S; Cheunwattana P
    J Med Assoc Thai; 2010 Feb; 93(2):154-60. PubMed ID: 20301994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Kagan KO; Wright D; Baker A; Sahota D; Nicolaides KH
    Ultrasound Obstet Gynecol; 2008 Jun; 31(6):618-24. PubMed ID: 18461550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.